Trial · NCT00635648
Adverse events27
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 27
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cardiac Failure | Cardiac disorders | Caspofungin 50 mg q.d. IV | 4 | 63 | 4 |
| other | Abdominal Pain | Gastrointestinal disorders | Caspofungin 50 mg q.d. IV | 4 | 63 | 4 |
| other | Oedema | General disorders | Caspofungin 50 mg q.d. IV | 4 | 63 | 4 |
| other | Pyrexia | General disorders | Caspofungin 50 mg q.d. IV | 5 | 63 | 7 |
| other | Alanine Aminotransferase Increased | Investigations | Caspofungin 50 mg q.d. IV | 10 | 63 | 10 |
| other | Aspartate Aminotransferase Increased | Investigations | Caspofungin 50 mg q.d. IV | 9 | 63 | 10 |
| other | Blood Albumin Decreased | Investigations | Caspofungin 50 mg q.d. IV | 6 | 63 | 6 |
| other | Blood Bilirubin Increased | Investigations | Caspofungin 50 mg q.d. IV | 7 | 63 | 11 |
| other | Blood Calcium Decreased | Investigations | Caspofungin 50 mg q.d. IV | 5 | 63 | 9 |
| other | Blood Creatinine Increased | Investigations | Caspofungin 50 mg q.d. IV | 7 | 63 | 8 |
| other | Blood Glucose Increased | Investigations | Caspofungin 50 mg q.d. IV | 4 | 63 | 4 |
| other | Blood Potassium Decreased | Investigations | Caspofungin 50 mg q.d. IV | 25 | 63 | 30 |
| other | Blood Sodium Decreased | Investigations | Caspofungin 50 mg q.d. IV | 4 | 63 | 4 |
| other | Blood Urea Increased | Investigations | Caspofungin 50 mg q.d. IV | 5 | 63 | 5 |
| other | Protein Total Decreased | Investigations | Caspofungin 50 mg q.d. IV | 6 | 63 | 6 |
| other | Rash | Skin and subcutaneous tissue disorders | Caspofungin 50 mg q.d. IV | 5 | 63 | 5 |
| other | Platelet Count Decreased | Investigations | Caspofungin 50 mg q.d. IV | 5 | 63 | 5 |
| serious | Cardiac Failure | Cardiac disorders | Caspofungin 50 mg q.d. IV | 1 | 63 | 1 |
| serious | Cardio-Respiratory Arrest | Cardiac disorders | Caspofungin 50 mg q.d. IV | 1 | 63 | 1 |
| serious | Vision Blurred | Eye disorders | Caspofungin 50 mg q.d. IV | 1 | 63 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00635648/events